{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:42:16Z","timestamp":1767339736288,"version":"build-2065373602"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.hoc.2008.07.014","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T09:21:01Z","timestamp":1225185661000},"page":"979-996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Cutaneous T-cell Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Frederick","family":"Lansigan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaehyuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine M.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2008.07.014_bib1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1056\/NEJMra032810","article-title":"The pathogenesis of mycosis fungoides","volume":"350","author":"Girardi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2008.07.014_bib2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.0303-6987.2005.00495.x","article-title":"WHO\/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects","volume":"32","author":"Burg","year":"2005","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.hoc.2008.07.014_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1182\/blood.V31.6.719.719","article-title":"The ultrastructure of an abnormal cell in S\u00e9zary syndrome","volume":"31","author":"Lutzner","year":"1968","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/jnci\/81.20.1560","article-title":"Mycosis fungoides in relation to environmental exposures and immune response: a case-control study","volume":"81","author":"Whittemore","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2008.07.014_bib8","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archderm.1987.01660260066015","article-title":"A case-control study of possible causative factors in mycosis fungoides","volume":"123","author":"Tuyp","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2001.tb03712.x","article-title":"Association between Sezary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma","volume":"941","author":"Abrams","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.hoc.2008.07.014_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1469-0691.2003.00594.x","article-title":"No evidence of skin infection with Chlamydia pneumoniae in patients with cutaneous T cell lymphoma","volume":"9","author":"Rossler","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.hoc.2008.07.014_bib11","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood.V88.8.3004.bloodjournal8883004","article-title":"Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus","volume":"88","author":"Pancake","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00042560-199612010-00003","article-title":"The difficulty of detecting HTLV-1 proviral sequences in patients with mycosis fungoides","volume":"13","author":"Pancake","year":"1996","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.hoc.2008.07.014_bib13","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood.V80.6.1537.1537","article-title":"Human lymphotropic retroviruses associated with mycosis fungoides: evidence that human T-cell lymphotropic virus type II (HTLV-II) as well as HTLV-I may play a role in the disease","volume":"80","author":"Zucker-Franklin","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib14","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1073\/pnas.88.17.7630","article-title":"Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides","volume":"88","author":"Zucker-Franklin","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2008.07.014_bib15","first-page":"725","article-title":"Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.hoc.2008.07.014_bib16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0046-8177(85)80177-5","article-title":"Histologic assessment of lymph nodes in mycosis fungoides\/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system","volume":"16","author":"Sausville","year":"1985","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2008.07.014_bib17","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood.V79.12.3293.3293","article-title":"Prognostic implications of evaluation for lymph node involvement by T-cell antigen receptor gene rearrangement in mycosis fungoides","volume":"79","author":"Lynch","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib18","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/1097-0142(19930801)72:3<726::AID-CNCR2820720316>3.0.CO;2-P","article-title":"Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sezary syndrome","volume":"72","author":"Graham","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.014_bib19","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2008.07.014_bib20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/Sezary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ajcp\/92.6.747","article-title":"Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases","volume":"92","author":"Salhany","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.hoc.2008.07.014_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0190-9622(97)70212-3","article-title":"Prognostic factors and evaluation of mycosis fungoides and Sezary syndrome","volume":"37","author":"Toro","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.1995.01690210033005","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib24","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1987.5.2.208","article-title":"Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis","volume":"5","author":"Dmitrovsky","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib27","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T\u00a0cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2340\/00015555655358","article-title":"Topical nitrogen mustard in early mycosis fungoides. A 12-year experience","volume":"65","author":"Zachariae","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.hoc.2008.07.014_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1529-8019.2006.00083.x","article-title":"Treatment of cutaneous T-cell lymphoma with retinoids","volume":"19","author":"Zhang","year":"2006","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.hoc.2008.07.014_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib34","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib36","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.1992.01680170063007","article-title":"Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/archderm.136.6.748","article-title":"Narrowband TL-01 phototherapy for patch-stage mycosis fungoides","volume":"136","author":"Clark","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early-stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archderm.135.11.1377","article-title":"Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides","volume":"135","author":"Hofer","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib40","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0190-9622(92)70142-3","article-title":"Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"26","author":"Jones","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0889-8588(03)00108-4","article-title":"Total skin electron beam radiotherapy for patients who have mycosis fungoides","volume":"17","author":"Jones","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2008.07.014_bib42","first-page":"1985","article-title":"Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome)","volume":"85","author":"Jones","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.014_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1073>3.0.CO;2-R","article-title":"Induction of human tumor-loaded dendritic cells","volume":"91","author":"Berger","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2008.07.014_bib44","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1523-1747.ep12363378","article-title":"The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens","volume":"107","author":"Berger","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2008.07.014_bib46","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0889-8588(03)00106-0","article-title":"Selective immunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow","volume":"17","author":"Girardi","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2008.07.014_bib47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2008.07.014_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1523-1747.ep12388985","article-title":"Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile","volume":"103","author":"Saed","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib49","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000096191","article-title":"Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome","volume":"213","author":"Fierro","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.hoc.2008.07.014_bib50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.hoc.2008.07.014_bib51","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hoc.2008.07.014_bib52","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-101-4-484","article-title":"Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas","volume":"101","author":"Bunn","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2008.07.014_bib53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(05)66242-3","article-title":"Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma","volume":"350","author":"Dippel","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2008.07.014_bib55","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib56","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/318467a0","article-title":"Reconstitution of functional receptor for human interleukin-2 in mouse cells","volume":"318","author":"Hatakeyama","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2008.07.014_bib57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1126\/science.1631559","article-title":"Cloning of the gamma chain of the human IL-2 receptor","volume":"257","author":"Takeshita","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.hoc.2008.07.014_bib58","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1073\/pnas.86.6.1982","article-title":"Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies","volume":"86","author":"Tsudo","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hoc.2008.07.014_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-006-9060-0","article-title":"Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey","volume":"27","author":"Waldmann","year":"2007","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.hoc.2008.07.014_bib60","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.seminoncol.2005.12.017","article-title":"Clinical experience with denileukin diftitox (ONTAK)","volume":"33","author":"Foss","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib61","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1084\/jem.167.2.612","article-title":"Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2\u00a0fusion protein","volume":"167","author":"Bacha","year":"1988","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2008.07.014_bib62","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.3816\/CLM.2000.s.005","article-title":"DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology","volume":"1","author":"Foss","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.hoc.2008.07.014_bib63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3816\/CLM.2006.n.059","article-title":"Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox","volume":"7","author":"Chin","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.hoc.2008.07.014_bib65","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib66","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2002-01-0300","article-title":"Immunomodulatory effects of RXR retinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox","volume":"100","author":"Gorgun","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib68","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2133.2002.04966.x","article-title":"Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides","volume":"147","author":"Mao","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib69","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1523-1747.1999.00507.x","article-title":"Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas","volume":"112","author":"McGregor","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib70","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.20021726","article-title":"Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma","volume":"197","author":"Kari","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2008.07.014_bib71","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2006-12-061507","article-title":"Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome","volume":"110","author":"Shin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib72","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1200\/JCO.2005.11.353","article-title":"Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73","volume":"23","author":"van Doorn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib73","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1523-1747.2003.12496.x","article-title":"Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides","volume":"121","author":"Scarisbrick","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib74","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.0022-202x.2001.01682.x","article-title":"Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sezary syndrome","volume":"118","author":"Scarisbrick","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"Johnstone","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2008.07.014_bib76","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib77","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"125","author":"Zhang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.hoc.2008.07.014_bib78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib79","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0925-4439(02)00073-X","article-title":"Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents","volume":"1587","author":"Schramm","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.hoc.2008.07.014_bib81","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminoncol.2007.11.003","article-title":"Pharmacology and mechanism of action of forodesine, a T-cell targeted agent","volume":"34","author":"Gandhi","year":"2007","journal-title":"Semin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib82","first-page":"122","article-title":"Response to oral forodesine in refractory cutaneous t-cell lymphoma: interim results of a phase I\/II study","volume":"110","author":"Duvic","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2008.07.014_bib83","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T cell lymphoma","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.hoc.2008.07.014_bib84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ctrv.2006.08.006","article-title":"Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma","volume":"33","author":"Whittaker","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hoc.2008.07.014_bib85","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2008.07.014_bib86","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib87","first-page":"2731","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase II studies in refractory cutaneous T-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2008.07.014_bib88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.hoc.2008.07.014_bib89","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib90","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.014_bib91","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib92","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib93","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.014_bib94","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2008.07.014_bib95","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8","article-title":"Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma","volume":"86","author":"Akpek","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2008.07.014_bib96","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","article-title":"T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement","volume":"114","author":"Olavarria","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2008.07.014_bib97","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858808001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:51:22Z","timestamp":1760183482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858808001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0889858808001081"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.014","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous T-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2008.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}